Long-term follow-up for babies with abnormal immune screening
Part of Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study follows babies who had an abnormal newborn screening for severe immune problems. It aims to track their health over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child had a positive result on the routine newborn blood spot test (Guthrie test).
- A specialist (pediatric immunologist) has already confirmed the positive result with a special blood test that looks at immune cells.
- You have not objected to having your child's medical data collected for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
This study looks at how the immune system works in people who have abnormal immune function, often shown by unusual or repeated infections or long-lasting inflammation. It may involve tests using blood samples and storage of blood for future research.
This study looks at what it feels like for people to go through screening for SCID (a rare immune condition). It may help improve the screening process and support for patients and families.
This study checks children in pediatric intensive care for possible “immune system problems” after a severe infection. The goal is to find primary immunodeficiencies early, which may change follow-up and treatment for the child’s immune health.
This study screens people who may have an inherited immune system condition (like problems with immune cell growth or death) and their blood relatives. The goal is to understand the condition better by collecting blood samples for testing.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
Hear when a new Severe Combined Immunodeficiencies (SCID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.